Skip to main navigation

+44 (0)20 8154 4600
info@achillestx.com

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Press Releases

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Year

All News
2024
2023
2022
2021
2020
2019
2018
2017
2016

Aug 4 2023

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Read More +

Jun 12 2023

Achilles Therapeutics to Present at Upcoming Conferences

Read More +

May 10 2023

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Read More +

May 10 2023

Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

Read More +

Apr 25 2023

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

Read More +

Apr 25 2023

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Read More +

Apr 17 2023

Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Read More +

Mar 7 2023

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

Read More +

Dec 20 2022

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More +

Dec 6 2022

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

Read More +

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Print Page

RSS Feeds

Email Alerts

Contact IR

Home
About Us
Science
Publications
Pipeline
Investors & Media
Work with us
Contact

UK Headquarters:
Achilles Therapeutics plc
245 Hammersmith Road
London
W6 8PW, UK

US Headquarters:
Achilles Therapeutics US, Inc.
401 N. Broad Street
Suite M121
Philadelphia, PA 19108

+44 (0)20 8154 4600
info@achillestx.com

© Copyright - Achilles Therapeutics plc.

Achilles Therapeutics plc (13027460) is registered in England and Wales. The registered office is at 245 Hammersmith Road, London, W6 8PW.

Privacy & Cookie Policy

Terms & Conditions